Zihe Zhang
Zihe Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Fangfang Lu
State Key Laboratory of Ophthalmology; Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science; Guangdong Provincial Clinical Research Center for Ocular Disease, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
1 shared publication - Jia Zhang
Department of Ophthalmology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China
1 shared publication - Jiahuan Yi1 shared publication
- Qiguo Xiao
Department of Ophthalmology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China
1 shared publication - Shigang Xia1 shared publication
- Xujie Deng1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Stem Cells International
- Vol. 2026 (1)
Mechanisms of Mesenchymal Stem Cell‐Derived Exosomes in Dry Eye Disease: From Inflammation Pathways to Therapeutic Prospects
Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell‐derived exosomes (MSC‐Exos) offer promising anti‐inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC‐Exos’ molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF‐κB signaling axis, the IRAK1/TRAF6/NF‐κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC‐Exos ameliorate the ocular surface inflammatory microenvironment by modulating the Th17/Treg immune balance via the gut–eye axis and facilitating FBXW7‐mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long‐term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC‐Exos as precision biologics for DED.
- 1 January 2026
- Published by Wiley in Stem Cells International
- Vol. 2026 (1)
Open AccessMechanisms of Mesenchymal Stem Cell‐Derived Exosomes in Dry Eye Disease: From Inflammation Pathways to Therapeutic Prospects
Dry eye disease (DED) is a chronic ocular surface disorder triggered by tear film imbalance, in which inflammatory disruption of immune homeostasis constitutes the core pathological mechanism. Mesenchymal stem cell‐derived exosomes (MSC‐Exos) offer promising anti‐inflammatory therapeutic potential through immune modulation, tissue repair, and their inherently low immunogenicity. This review elucidates MSC‐Exos’ molecular regulation of DED inflammation, demonstrating their suppression of the TLR4/NF‐κB signaling axis, the IRAK1/TRAF6/NF‐κB cascade reaction, the STAT3 transcriptional regulatory network, and the NLRP3 inflammasome activation pathway, while revealing a synergistic mechanism through which MSC‐Exos ameliorate the ocular surface inflammatory microenvironment by modulating the Th17/Treg immune balance via the gut–eye axis and facilitating FBXW7‐mediated ubiquitination degradation pathways. Despite this therapeutic potential, clinical translation is hampered by exosomal heterogeneity, difficulties in standardization, and suboptimal delivery efficiency and long‐term efficacy. Future progress will require the integration of nanotechnology and gene editing to enhance therapeutic functionality, ultimately positioning MSC‐Exos as precision biologics for DED.